↓ Skip to main content

Phase III Trial of Chemotherapy Plus Radiotherapy Compared With Radiotherapy Alone for Pure and Mixed Anaplastic Oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402

Overview of attention for article published in Journal of Clinical Oncology, June 2006
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (91st percentile)
  • High Attention Score compared to outputs of the same age and source (88th percentile)

Citations

dimensions_citation
564 Dimensions

Readers on

mendeley
208 Mendeley
citeulike
2 CiteULike
connotea
2 Connotea
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Phase III Trial of Chemotherapy Plus Radiotherapy Compared With Radiotherapy Alone for Pure and Mixed Anaplastic Oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402
Published in
Journal of Clinical Oncology, June 2006
DOI 10.1200/jco.2005.04.3414
Pubmed ID
Authors

Gregory Cairncross, Brian Berkey, Edward Shaw, Robert Jenkins, Bernd Scheithauer, David Brachman, Jan Buckner, Karen Fink, Luis Souhami, Normand Laperierre, Minesh Mehta, Walter Curran

Abstract

Anaplastic oligodendroglioma (AO) and anaplastic oligoastrocytoma (AOA) are treated with surgery and radiotherapy (RT) at diagnosis, but they also respond to procarbazine, lomustine, and vincristine (PCV), raising the possibility that early chemotherapy will improve survival. Furthermore, better outcomes in AO have been associated with 1p and 19q allelic loss.

Mendeley readers

The data shown below were compiled from readership statistics for 208 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 4 2%
Japan 3 1%
Canada 2 <1%
India 1 <1%
Brazil 1 <1%
Australia 1 <1%
United Kingdom 1 <1%
France 1 <1%
Spain 1 <1%
Other 2 <1%
Unknown 191 92%

Demographic breakdown

Readers by professional status Count As %
Researcher 42 20%
Other 33 16%
Student > Ph. D. Student 21 10%
Student > Postgraduate 20 10%
Student > Master 19 9%
Other 61 29%
Unknown 12 6%
Readers by discipline Count As %
Medicine and Dentistry 141 68%
Agricultural and Biological Sciences 20 10%
Neuroscience 5 2%
Biochemistry, Genetics and Molecular Biology 5 2%
Social Sciences 3 1%
Other 11 5%
Unknown 23 11%

Attention Score in Context

This research output has an Altmetric Attention Score of 14. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 July 2018.
All research outputs
#1,045,895
of 13,205,256 outputs
Outputs from Journal of Clinical Oncology
#2,791
of 13,311 outputs
Outputs of similar age
#5,793
of 68,887 outputs
Outputs of similar age from Journal of Clinical Oncology
#12
of 118 outputs
Altmetric has tracked 13,205,256 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 91st percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 13,311 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 16.0. This one has done well, scoring higher than 78% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 68,887 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 91% of its contemporaries.
We're also able to compare this research output to 118 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 88% of its contemporaries.